Introduction
Early antiretroviral treatment (ART) is recommended for HIV-infected infants based on significant benefits of early versus eligibility-deferred ART [1] . Prior to widespread ART use, some HIV-infected untreated children had long-term nonprogression (LTNP) [2] . It is plausible that some children who would be LTNP without therapy, as well as others who control virus following early ART, could benefit from treatment interruption after immune recovery. This approach could reduce ART toxicity or resistance and preserve ART regimens for later in life.
There are several differences between pediatric and adult treatment interruption. In children, it is frequently possible to diagnose HIV soon after infection, which makes treatment during primary HIV infection more feasible than in adults. Initiation of ART during primary HIV may enable sustained treatment interruption with posttreatment virologic control (PTC) as observed in the 'Mississippi baby' and in a teen from France [3, 4] . The ANRS VISCONTI study noted durable PTC among adults who started ART during primary HIV [5] and had treatment interruption, although PTC may be infrequent [6, 7] . Immune outcomes and safety of treatment interruption may also differ between children and adults. The presence of functional thymus in infants could enhance immune recovery following early ART [8] . Although some adult treatment interruption studies, notably the SMART trial, observed increased cardiovascular mortality risk with treatment interruption, these findings have not been replicated in children [9] [10] [11] [12] . In a large pediatric treatment interruption trial, PENTA-11, more than half of children randomized to treatment interruption completed a 48-week period of treatment interruption without meeting criteria to restart ART [12] . Importantly, 2-year follow-up noted no differences in long-term outcomes, including cognitive or growth outcomes in children with treatment interruption versus continued ART in this trial [13] . In adults, ART plays a dual role in treatment and prevention and treatment interruptions could undermine HIV prevention; however, this is not the case for children until adolescence [14, 15] . High rates of unplanned treatment interruptions, poor adherence, and resistance are noted in children, leading to the possibility of exhausting regimens for children who start lifelong ART in infancy [16] [17] [18] . Thus, on balance, strategic treatment interruptions may permit a longer life period in which ARTs are effective for some children.
We hypothesized that infants treated early in HIV infection may safely sustain treatment interruption, making this a viable approach to preserving limited ART options for infants. We conducted a randomized clinical trial (RCT) to compare outcomes of children who were treated in the first year of life and randomized following 2-year ART to a single treatment interruption versus continued treatment.
Methods
Study design, ethical approvals, and trial data and safety monitoring The optimizing pediatric HIV-1 (OPH-03) treatment study (NCT00428116) was an RCT in which HIVinfected infants, who completed at least 2 years ART and attained immune reconstitution and normalized growth, were randomized to treatment interruption or continued ART. Written informed consent was obtained from caregivers of children. The study received ethical approval from the Institutional Review Boards at the University of Washington and the Ethical Review Committee at Kenyatta National Hospital (KNH). An independent Data and Safety Monitoring Board (DSMB) reviewed the study at 6-month intervals.
Recruitment of trial participants
HIV-infected infants were identified from prevention of mother-to-child HIV transmission (PMTCT) sites in Nairobi, KNH wards, and the KNH HIV Treatment Clinic. Initial eligibility criteria restricted to infants less than 4 months of age were extended to less than 13 months to include infants who may have acquired postnatal HIV and infants already on ART who started at less than 13 months. For these children, pre-ART clinical, CD4 þ cell count and CD4%, and growth data were abstracted from medical records.
Enrollment and prerandomization follow-up
At enrollment, a questionnaire was administered and physical examination was performed; blood was collected for CD4 þ cell count and CD4%, viral load, lipids, and liver function tests. Children were initiated on ART (PMTCT-exposed children received lopinavir/ritonavir, lamivudine, and zidovudine; children with no prior PMTCT exposure received nevirapine, lamivudine, and zidovudine; later enrollees received abacavir instead of zidovudine). Generic antiretroviral medications were provided by PEPFAR. These medications are on the WHO pre-qualified list meeting US FDA standards. Children were seen monthly for clinical assessment and anthropometry with 3-month interval blood collections for CD4 þ cell count and CD4% (6-monthly), HIV RNA, complete blood count, lipids (6-monthly), and liver transaminases.
Randomization
After 24 months of ART, infants were randomized to continue ART (continued arm) or interrupt ART (TI arm) and followed for 18 months. Prior to randomization, caregivers were counseled using a standard script and re-consented for randomization. Eligibility criteria for randomization included: normal growth [weight-for-height (WHZ > À0.5) and weightfor-age (WAZ > À1.65 or 5th percentile) with no recent weight loss (crossing two major weight-for-age percentiles in the last 3 months)], CD4% ! 25%, no recent opportunistic infections including tuberculosis, and willingness for randomization. Block randomization was conducted with variable block sizes generated using Stata 8.0 ralloc.ado v2.2.1 (StataCorp, College Station, Texas, USA). Treatments were allocated in 1 : 1 ratio. All study investigators were blinded to block number, block size, and sequence in the block. Treatments were assigned in preprepared sealed, opaque envelopes ordered in the sequence of treatment assignments. Once an infant's eligibility was determined, the first available allocation envelope was assigned to the infant.
Treatment interruption
To prevent resistance, nucleoside reverse transcriptase inhibitors (NRTIs) were continued for 2 weeks after stopping non-nucleoside reverse transcriptase inhibitors (NNRTIs) to allow for NNRTI decay.
Postrandomization follow-up
After randomization, children were reviewed after 2 weeks and monthly to 18 months with anthropometric measurements, WHO staging, and adverse event determination. Blood was collected at 3-month intervals for CD4 þ cell count and CD4% and viral load.
Restart of antiretroviral treatment in the treatment interruption arm Criteria for ART restart were CD4% less than 20-25% (CD4% threshold changed from 20 to 25% in November 2010 following a change in WHO guidelines for ART initiation) or a decrease greater than one-third of the peak CD4 þ cell count or CD4%, more advanced WHO stage, or weight loss (drop in weight-for-age percentile to less than 5th percentile or weight crossing more than 2 major weight-for-age percentiles). Once a child restarted ART, there was no further interruption.
Sample size
The targeted sample size was 150 enrolled children, of which 100 would be randomized. Using data from a previous perinatal HIV study in Nairobi, the average weight-for-height z-score (WHZ) among HIV-uninfected and HIV-infected children at $20 months was À0.7002 with a SD of 0.8529 [19] . Assuming the mean WHZ among the continuous ART children was À0.7002, the same SD for both groups, a two-sided test, significance level of 0.05, and 10% loss to follow-up: with 50 children in each trial arm (45 with complete follow-up), there was an estimated 80% power to exclude differences in WHZ of 0.50 or larger between RCTarms.
Laboratory methods
CD4 þ cell counts were determined at the University of Nairobi using FACSCount (BD Biosciences, Franklin Lakes, New Jersey, USA) and CD4% using the Humalyser hematology analyzer. HIV RNA measurements were conducted at the Fred Hutchinson Cancer Research Center in Seattle, using the Gen-Probe HIV-1 RNA assay (Gen Probe, San Diego, California, USA). Genotypic resistance testing was conducted in Nairobi using a population-based Sanger sequencing method described previously [20] . Interpretation of the sequences conferring resistance utilized the Stanford University HIV Drug resistance Database (http://hivdb.stanford.edu/).
Statistical analysis
All analyses were conducted using Stata SE version 12 (StataCorp, College Station, Texas, USA). To assess adequacy of randomization, baseline characteristics were compared between trial arms using the Wilcoxon rank sum tests and Fisher's exact tests. The primary outcome was comparison of growth and serious adverse events (SAEs) postrandomization between arms. Plasma HIV RNA, CD4 þ cell count and percentage, and morbidity were also compared. Growth was measured as weight-for-age z-scores (WAZ), WHZ, and heightfor-age z-scores (HAZ). Primary outcomes were compared using the Wilcoxon rank sum tests (continuous variables) and Cox regression (time-to-event variables) with Anderson-Gill methods for recurrent events, as appropriate. Time to death was compared using the log-rank statistic.
Results

Baseline characteristics and prerandomization follow-up
Between September 2007 and August 2010, 140 HIVinfected children were enrolled, and 121 enrolled children initiated ART (80 initiated ART in study, 41 previously on ART), of whom 18 died, 8 were lost to follow-up, 3 withdrew prior to randomization, 75 completed 2 years of ART, and 17 had not completed 2-year ART (Fig. 1 ). The prerandomization cohort has been described [21] . Among infants enrolled prior to ART, pre-ART mortality was high despite short median time to ART (2 weeks from diagnosis) [20] . Of 75 children who completed 2-year ART, 29 did not meet randomization eligibility criteria or had evidence of nonadherence, treatment switch, or unplanned treatment interruption; four children were pending randomization when the DSMB recommended stopping the study. Forty-two children were randomized.
Characteristics of randomized children
Pre-ART (over 2 years before randomization), median age of the 42 infants was 5.0 months and the pre-ART CD4% was 23 and 19% in the continued and treatment interruption arms, respectively (P ¼ 0.2) ( Fig. 1 , Table 1 ). Initial ART regimens (38% received protease inhibitor and the remainder NNRTI regimens) and anthropometric measures pre-ART were comparable between arms. At randomization, time on ART, clinical, immunologic, virologic, and growth characteristics were similar between trial arms. Median CD4% was 33 versus 34% in the continued versus treatment interruption arm, respectively (P ¼ 0.9). Plasma viral load was comparable with each arm median less than 150 copies/ml.
Data safety monitoring board discontinuation of randomization
In July 2011, the DSMB determined that although randomization into the treatment interruption arm was safe, most children met ART restart criteria at 3-months post-treatment interruption. The DSMB recommended stopping randomization due to low treatment interruption durability and that randomized children complete 18-month follow-up with the option of restarting ART depending on caregiver preference.
Postrandomization follow-up
There were 30.6 person-years of follow-up in the continued arm and 32.1 person-years of follow-up in the treatment interruption arm. There was one loss to follow-up and one withdrawal, both in the continued arm. Among 21 children randomized to treatment interruption, 17 (81%) met criteria for ART restart. Fourteen (66%) experienced a CD4% drop to 25% or less within 3 months and one child after 6 months; one child met criteria of a greater than one-third drop from peak CD4% at 15 months, and one had a worsened WHO stage at 15 months post-treatment interruption. Four children (19%) never met ART restart criteria. Following the DSMB recommendation, two caregivers restarted ART at 9 and 12 months, whereas two children remained on treatment interruption till 12 and 15 months until the team advised restart due to inability to monitor children following study completion. Median time off treatment for children in the treatment interruption arm was 4.3 months (interquartile range, 3.7, 9.7).
Immunologic responses following treatment interruption and restart
Following treatment interruption, median CD4% dropped from 34 to 23% at 3-months postrandomization ( treatment interruption arm at 3-months postrandomization (median 23 versus 37% in treatment interruption versus continued, P < 0.001). Among the 17 children who met ART restart criteria, median increase in CD4% was 8% at 3 months following ART restart ( Fig. 2a ). CD4% was identical between trial arms at 18 months (CD4% 35% in each arm, P ¼ 0.92).
Growth and morbidity At 6, 12, and 18 months postrandomization, the median WAZ was À0.42, À0.54, and À0.57 in the continued arm, respectively and À0.30, À0.29, and À0.17 in the treatment interruption arm, respectively ( Table 2 , Fig. 2c ). There were no significant differences in WAZ, WHZ, and HAZ between arms ( Fig. 2c-e ).
Incidence of serious adverse events
SAEs were infrequent and did not differ between arms. In the continued arm, one infant died (incidence 3.3 per 100 person-years). In the treatment interruption arm, one infant was hospitalized for cellulitis (Grade 3) (incidence 3.1 per 100 person-years) ( Table 2 ). Children in the treatment interruption arm had a trend for higher incidence of lymphadenopathy, whereas children on continued ART had significantly higher incidence of hypercholesterolemia. During 6-months postrandomization, those with shorter treatment interruption had a higher incidence of lymphadenopathy (135.8 cases per 100 person-years), than those with longer treatment interruption had less lymphadenopathy (31. median of 6.02 log 10 copies/ml versus undetectable 2.18 log 10 copies/ml (<150 copies/ml) at 3-months postrandomization (P < 0.001), Fig. 2b . Following ART restart, median plasma viral load dropped by 3.49 log 10 copies/ml after 6-months postrestart. By 18 months, median viral levels were undetectable in continued and treatment interruption arms (P ¼ 0.92); however, 6 of 18 (33%) children in the continued arm had viral load more than 1000 copies/ml versus 5 (24%) of 21 children in the treatment interruption arm (P ¼ 0.72) ( Table 2) .
Prerandomization, 5 children in the continued arm had viral load more than 1000 copies/ml, of whom one did not amplify, two tested without resistance, and two tested with resistance (M46I, I54V, V82F, Y188L, H221Y, M184V, D67N; and M184V, K103N); five children in the treatment interruption arm had viral load more than 1000 copies/ml, of whom two were not tested, one tested without resistance, and two tested with resistance (Y181C, M184V; and A98AG, K101AE, G190A, M184V). Postrandomization, 10 in the continued arm 2308 AIDS 2016, Vol 30 No 15 had a viral load more than 1000 copies/ml, of whom four were tested and had no resistance; all 21 in the treatment interruption arm had at least one viral load more than 1000 copies/ml, of whom 11 tested without resistance and two tested with resistance (K103N; and A98AG, K101AEKT, G190AG, M184MV).
Characteristics of children who sustained longer treatment interruption
Although most children rapidly met ART restart criteria following treatment interruption, seven (one-third) sustained longer treatment interruption (>5 months). Patterns of viral load and CD4% before, during, and after treatment interruption are summarized in Fig. 3 . Because viral loads were measured retrospectively and were not part of eligibility criteria, some children were not virally suppressed at randomization. Two children with viremia prior to treatment interruption had minimal changes in CD4% after treatment interruption (nos. 041 and 045). In children with longer treatment interruption, ID nos. 010 and 076 had viral load decline after initial high levels. All children had rapid viral decline following restarting ART.
Children in the treatment interruption arm who sustained treatment interruption longer than 3 months had similar nadir pre-ART CD4% to those who restarted ART by 3 months after treatment interruption but had a higher CD% at randomization (randomization CD4%: 39 versus 33% for treatment interruption more than 3 versus less than 3 months; P ¼ 0.04) ( Table 3 ).
Discussion
In this study (OPH), which involved infants who started ART before 13 months of age, received at least 2 years of ART, and were randomized to treatment interruption versus continued ART, most children in the treatment interruption arm met criteria for restarting ART within 3 months of treatment interruption. During postrandomization follow-up, treatment interruption was safe and 18-month CD4%, viral load, incidence of severe adverse events, and growth in children in the treatment interruption arm did not differ from those who continued ART. These findings complement those from the PENTA-11 trial that evaluated treatment interruption in older children and the CHER trial that evaluated treatment interruption among children who started ART in infancy, but lacked a continued ART comparison group. Collectively, these studies suggest that monitored short-term treatment interruption does not increase adverse effects over 1-2 years following the treatment interruption and ART restart period.
We observed a lower proportion of children (<20%) sustaining treatment interruption (not meeting ART restart criteria for more than 3 months) compared with the CHER study [median treatment interruption duration 70 weeks in CHER at trial end among children with a similar duration of early ART prior to treatment interruption (96 weeks) as in our study] or the PENTA-11 study (60% had treatment interruption up to 48 weeks)
Optimizing pediatric HIV treatment Wamalwa et al. 2309 Table 3 . Comparison of treatment interruption children who met antiretroviral treatment restart criteria at 3 months to those with met antiretroviral treatment restart criteria later. Excludes infants already on ART at enrollment who did not have this information.
Characteristics
[10,12]. One reason for our observed shorter treatment interruption is that our CD4% criterion for ART restart was higher (25%) to align with later WHO recommendations [22] , whereas PENTA-11 and CHER used CD4% of 20% eligibility for ART restart. Small pediatric treatment interruption studies have observed CD4% increase following initial decline as HIV-1 specific immunity increases in response to viremia emerging after treatment interruption [23] . Lower CD4% criteria for ART restart may permit time to develop HIV-specific immunity to contain virus and regain immune reconstitution. Another potential reason for shorter treatment interruption in the OPH cohort is the more advanced HIV disease pre-ART. CHER infants started ART while being asymptomatic with CD4% more than 25% [1] . In OPH, over half of children had CD4% less than 25% and WHO stage 3-4 at ART initiation. Children in OPH were older at ART initiation (median 5 versus 1.9 months in CHER). We extended age-eligibility to broaden generalizability to postpartum-infected and later-diagnosed infants with the hypothesis that infants treated in the first year of life could restore immune function. Consistent with this hypothesis, we found that nadir pre-ART CD4% was not as predictive of treatment interruption duration as CD4% following 2-year ART, suggesting that some infants may safely sustain treatment interruption despite a low nadir CD4%.
In the PENTA-11 trial, 60% completed treatment interruption for 48 weeks with no serious adverse effects [12]. Children in PENTA-11 were older (median age 9 years) and received ART longer (median 6 years) than in our study. Although the period of treatment interruption in OPH was shorter, we also observed prompt CD4% recovery and viral suppression following reinitiation of ART with no discernable differences in viral control or CD4% in treatment interruption children at 18 months post-treatment interruption. The incidence of serious clinical events in OPH was not elevated in the treatment interruption arm, suggesting that treatment interruption can be safe in the short-term with close monitoring. A higher CD4% at treatment interruption, rather than nadir CD4%, predicted treatment interruption durability in OPH, in contrast to PENTA-11 and SPARTAC (an adult treatment interruption trial following ART in primary HIV) studies, which observed that pre-ART immune status predicted treatment interruption durability or PTC [12, 24] . This suggests that both pre-ART and post-ART immune function may influence treatment interruption durability and PTC [25, 26] .
We did not identify post-treatment virologic controllers. This differs from the VISCONTI ANRS cohort [5] , but is consistent with other adult studies [6, 7] and preliminary data from children in the CHER study [27] . Most studies have had limited statistical power to estimate frequency of PTC (estimated 0-15%) [7] . We used immune, growth, and clinical criteria rather than viral suppression to identify children for treatment interruption and our data underscore limitations of a clinically guided approach to pediatric treatment interruption. Given the timing of ART initiation and slow suppression on ART in our cohort, children likely had large viral reservoirs at treatment interruption, which correlate with rapid rebound. In contrast to adults, in whom PTC has been observed following ART initiation within months of acute HIV, rapid progression in infants suggests need for more accelerated detection and treatment. Although our study suggests clinical safety of short treatment interruption, children with limited viral reservoirs following very early ART could have more to lose from treatment interruption than children such as those in our cohort, with more established reservoirs, because of potential to expand their viral reservoir [28] . Studies to determine whether shorter treatment pauses can safely reveal PTC are ongoing.
Several issues are uniquely relevant to pediatric treatment interruption. Children appear not to have morbidity risks noted in adult treatment interruption trials, with comparable morbidity in treatment interruption versus continued ART. Poor viral control and unplanned treatment interruptions contribute to poor outcomes in infants on ART, lending conceptual appeal to strategic treatment interruption to preserve regimen efficacy. We observed prompt declines in viral load following ART restart. Long-term virologic failure postrandomization was not uncommon (33%) in the continued arm and actually more frequent than in the treatment interruption arm (24%), although underpowered for comparison. This illustrates the challenges of ART adherence in children.
Our data suggest safety of short treatment interruption; however, it does not provide evidence to support longer treatment interruption in this population.
Limitations of our study include a small sample size and the short duration of treatment interruption. Thus, we may not have realized longer term risks or benefits of treatment interruption. Despite limited numbers, prevalence of hypercholesterolemia was higher in children in the continued arm. Increased incidence of lymphadenopathy in children with treatment interruption is consistent with an acute infection-like syndrome and has been consistently observed in treatment interruption studies. Incidence of lymphadenopathy was highest among those with short treatment interruption, suggesting that lymphadenopathy occurred in parallel with rapid CD4% decline and consequent ART restart in this group.
In summary, our study provides clinical trial evidence that children who initiate ART during early HIV do not have clinically discernable long-term adverse outcomes from brief-monitored treatment interruption. Our study did not identify any post-treatment controllers among infants started on ART. Complementary strategies such as immune therapies may be necessary to enhance likelihood of PTC [29] . The study also underscores need for improved ART regimens for young children [30] .
